Merck (MRK.N) is in talks to buy cancer drug developer Revolution Medicines (RVMD.O) in a $28 billion to $32 billion deal, the Financial Times reported on Thursday, citing a person familiar with the matter. Merck has been pursuing an acquisition of Revolution Medicines, however, a deal has not been finalised, the report said, citing people familiar with the matter, adding a tie-up would be at least several weeks away. Other large pharmaceutical groups were still circling the biotech and another suitor might yet prevail, the FT report said, adding a transaction is not a foregone conclusion.
Read the full article: Merck in Talks to Buy Biotech Revolution in up to $32B Deal, FT Reports //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/merck-talks-buy-biotech-revolution-medicines-ft-reports-2026-01-08/